Trial Results
Subjects receiving VT-122 showed a clinically meaningful improvement in lean body mass.
Of the subjects treated with VT-122, 50% showed a clinically meaningful gain of more than 5% in lean body mass; none of the subjects on the best supportive care control arm showed any gain (p<0.01)
Effect of VT-122 on Lean Body Mass
Weight losing advanced lung cancer patients not on chemotherap (Percent of subjects with more than 5% increase at 12 weeks)
